title: [Ruxolitinib prescription in myelofibrosis].
abstract: Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, which allows to hope that we will soon be able to change the natural evolution of this poor outcome disease. With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America. In France, ruxolitinib is now available, allowing its administration to symptomatic myelofibrosis patients.
authors.affiliation: CHU de Clermont-Ferrand, CHU Estaing, service d'hématologie clinique adulte et de thérapie cellulaire, université d'Auvergne CREaT-EA 7283, Inserm CIC-501, 63000 Clermont-Ferrand, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Lemal
authors.forename: Marie
authors.initials: M
authors.lastname: Robin
authors.forename: Aurélie
authors.initials: A
authors.lastname: Ravinet
authors.forename: Victoria
authors.initials: V
authors.lastname: Cacheux
authors.forename: Romain
authors.initials: R
authors.lastname: Guièze
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
mesh_terms: D004347:Drug Interactions; D006801:Humans; D053613:Janus Kinase 1 / Q000235:genetics; D053614:Janus Kinase 2 / Q000235:genetics; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000235:genetics; D009570:Nitriles; D010677:Philadelphia Chromosome; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D011720:Pyrazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines; D012074:Remission Induction; D013163:Splenomegaly / Q000188:drug therapy
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053613:Janus Kinase 1; D053614:Janus Kinase 2; D053612:Janus Kinases
keywords: myeloproliferative syndrome; primary myelofibrosis; ruxolitinib; splenomegaly